PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)

PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)

Copyright © 2023. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 250(2023) vom: 15. Mai, Seite 109296
1. Verfasser: Smith, E M D (VerfasserIn)
Weitere Verfasser: Aggarwal, A (BerichterstatterIn), Ainsworth, J (BerichterstatterIn), Al-Abadi, E (BerichterstatterIn), Avcin, T, Bortey, L, Burnham, J, Ciurtin, C, Hedrich, C M, Kamphuis, S, Lambert, L, Levy, D M, Lewandowski, L, Maxwell, N, Morand, E, Ozen, S, Pain, C E, Ravelli, A, Saad Magalhaes, C, Pilkington, C, Schonenberg-Meinema, D, Scott, C, Tullus, K, Beresford, M W, International cSLE T2T Task Force, Goilav, B, Marks, S, Oni, L
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Childhood-SLE Low disease activity T2T Treat-to-target cLLDAS cSLE Immunosuppressive Agents Prednisolone 9PHQ9Y1OLM
LEADER 01000caa a22002652c 4500
001 NLM354402366
003 DE-627
005 20250304132657.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2023.109296  |2 doi 
028 5 2 |a pubmed25n1181.xml 
035 |a (DE-627)NLM354402366 
035 |a (NLM)36934849 
035 |a (PII)S1521-6616(23)00075-X 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Smith, E M D  |e verfasserin  |4 aut 
245 1 0 |a PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS) 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 28.04.2023 
500 |a Date Revised 24.09.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2023. Published by Elsevier Inc. 
520 |a OBJECTIVE: To achieve a consensus-based definition of Low Disease Activity (LDA) for use in cSLE trials 
520 |a METHODS: The International cSLE T2T Task Force, comprising of paediatric rheumatologists/nephrologists, and adult rheumatologists undertook a series of Delphi surveys/consensus meetings to discuss, refine, and vote upon cSLE LDA criteria 
520 |a RESULTS: The Task Force agreed that LDA should be based upon the adult-SLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it applicable to cSLE (cLLDAS). They agreed upon five cLLDAS criteria: (1) SLE Disease Activity Index (SLEDAI)-2 K ≤4, with no activity in major organ systems; (2) no new features of lupus disease activity compared with the last assessment; (3) Physician Global Assessment score of ≤1 (0-3 scale); (4) prednisolone dose of ≤0.15 mg/kg/day, 7.5 mg/day/maximum; while on (5) stable antimalarials, immunosuppressives, and biologics 
520 |a CONCLUSIONS: A cSLE-appropriate definition of cLLDAS has been generated, maintaining alignment with the adult-SLE definition to promote life-course research 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Childhood-SLE 
650 4 |a Low disease activity 
650 4 |a T2T 
650 4 |a Treat-to-target 
650 4 |a cLLDAS 
650 4 |a cSLE 
650 7 |a Immunosuppressive Agents  |2 NLM 
650 7 |a Prednisolone  |2 NLM 
650 7 |a 9PHQ9Y1OLM  |2 NLM 
700 1 |a Aggarwal, A  |e verfasserin  |4 aut 
700 1 |a Ainsworth, J  |e verfasserin  |4 aut 
700 1 |a Al-Abadi, E  |e verfasserin  |4 aut 
700 1 |a Avcin, T  |e verfasserin  |4 aut 
700 1 |a Bortey, L  |e verfasserin  |4 aut 
700 1 |a Burnham, J  |e verfasserin  |4 aut 
700 1 |a Ciurtin, C  |e verfasserin  |4 aut 
700 1 |a Hedrich, C M  |e verfasserin  |4 aut 
700 1 |a Kamphuis, S  |e verfasserin  |4 aut 
700 1 |a Lambert, L  |e verfasserin  |4 aut 
700 1 |a Levy, D M  |e verfasserin  |4 aut 
700 1 |a Lewandowski, L  |e verfasserin  |4 aut 
700 1 |a Maxwell, N  |e verfasserin  |4 aut 
700 1 |a Morand, E  |e verfasserin  |4 aut 
700 1 |a Ozen, S  |e verfasserin  |4 aut 
700 1 |a Pain, C E  |e verfasserin  |4 aut 
700 1 |a Ravelli, A  |e verfasserin  |4 aut 
700 1 |a Saad Magalhaes, C  |e verfasserin  |4 aut 
700 1 |a Pilkington, C  |e verfasserin  |4 aut 
700 1 |a Schonenberg-Meinema, D  |e verfasserin  |4 aut 
700 1 |a Scott, C  |e verfasserin  |4 aut 
700 1 |a Tullus, K  |e verfasserin  |4 aut 
700 1 |a Beresford, M W  |e verfasserin  |4 aut 
700 0 |a International cSLE T2T Task Force  |e verfasserin  |4 aut 
700 1 |a Goilav, B  |e investigator  |4 oth 
700 1 |a Marks, S  |e investigator  |4 oth 
700 1 |a Oni, L  |e investigator  |4 oth 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 250(2023) vom: 15. Mai, Seite 109296  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:250  |g year:2023  |g day:15  |g month:05  |g pages:109296 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2023.109296  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 250  |j 2023  |b 15  |c 05  |h 109296